Apellis Pharmaceuticals, Inc. (FRA:1JK)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.49B +123.4% |
| Revenue (ttm) | 958.61M +42.5% |
| Net Income | 115.58M |
| EPS | 0.89 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 34.11 |
| Previous Close | 34.16 |
| Day's Range | 34.11 - 34.11 |
| 52-Week Range | 13.88 - 35.81 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glome... [Read more]
News
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Biogen said on Friday it had either paused or discontinued funding for most of Apellis Pharmaceuticals' research programs as it integrates the rare-disease drugs specialist it purchased for $5.6 bil...
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil...
Apellis Pharmaceuticals Quarterly report: Q1 2026
Apellis Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Why This Pharma Stock More Than Doubled Today
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.
Apellis Pharmaceuticals Transcript: M&A announcement
The acquisition adds two commercial-stage immunology products, expanding the portfolio into nephrology and rare diseases, and is expected to drive mid-to-high teens revenue growth for at least two years. The $5.6B deal, with additional CVR payments, is forecast to be accretive from 2027 and strengthens long-term growth prospects.
Apellis Pharmaceuticals Press release: M&A announcement
Apellis Pharmaceuticals issued a press release on March 31, 2026, disclosing material business information to investors.
Apellis Pharmaceuticals Slides: M&A announcement
Apellis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
Apellis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing three strategic pillars: SYFOVRE for geographic atrophy, EMPAVELI for rare kidney diseases, and a gene editing program, with strong launches and robust pipelines. Despite a revenue dip in 2025 due to market disruptions, underlying demand and future growth prospects remain strong.
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D.
Apellis Pharmaceuticals Earnings Call Transcript: Q4 2025
Steady commercial execution in 2025 drove strong pipeline progress and resilient demand for Syfovre and Empaveli, with robust financials and a stable outlook for 2026. Key innovations and clinical data support long-term growth and market leadership.
Apellis Pharmaceuticals Earnings release: Q4 2025
Apellis Pharmaceuticals released its Q4 2025 earnings on February 24, 2026, summarizing the period's financial results.
Apellis Pharmaceuticals Annual report: Q4 2025
Apellis Pharmaceuticals has published its Q4 2025 annual report on February 24, 2026.
Apellis Pharmaceuticals Slides: Q4 2025
Apellis Pharmaceuticals has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 24, 2026.
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual ...
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE)...
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter a...
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) w...
Apellis Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted strong market leadership in geographic atrophy, with Syfovre maintaining a 60% share and new innovations like a prefilled syringe and AI-driven imaging expected to drive future growth. Empaveli's rare disease launch exceeded expectations, and a robust pipeline targets further expansion.
Apellis Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference
Apellis Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.